Managing HIV Drug Resistance

July 8, 2021: Trends among heavily treatment-experienced PLWH; a new look at peripheral neuropathy factors; heart transplantation in PLWH; complications following successful HCV treatment.

June 17, 2021: PrEP awareness vs. PrEP willingness among young Black women; acute HIV infection during PrEP initiation; real-world PrEP efficacy; HIV rates by U.S. region among transgender people.

Four months after the approval of cabotegravir/rilpivirine, medical providers still face some tough questions about who might best benefit and how the medication might be covered.

Dec. 17, 2020: HIV-related mortality in the U.S.; trends in extensive multidrug resistance; 96-week fostemsavir data; statins for microbial cancer prevention.

Most people living with HIV will never need fostemsavir. But for those who do, the drug can be a life-saver—and that is pretty epic.

Nov. 5, 2020: Success of direct referrals at re-linking people to HIV care; stable housing = viral suppression; modern-day rates of virologic failure; how pharmacy type affects HIV treatment outcomes.

Oct. 29, 2020: Diabetes incidence on INSTIs vs. NNRTIs vs. protease inhibitors; can NRTIs fight diabetes?; from TDF to TAF in HIV/HBV-coinfected people; assessing neurocognitive impacts of older two-drug regimens.

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.

April 23, 2020: The corps of front-line care providers with HIV-specific experience is aging and retiring, leaving behind a growing need for quality care. We examine recent research and analysis that both describes that need and offers interventions to meet it.